Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVTX-009 Regimen 1 · 1 trial · 1 indication
HiSCR75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count, relative to Baseline.
| Arm | Type | Description |
|---|---|---|
| AVTX-009 Regimen 1 | EXPERIMENTAL | Patients will receive AVTX-009 regimen 1. |
| AVTX-009 Regimen 2 | EXPERIMENTAL | Patients will receive AVTX-009 regimen 2. |
| Placebo | PLACEBO_COMPARATOR | Patients will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| AVTX-009 Regimen 1 | DRUG | AVTX-009 will be administered as a subcutaneous injection every 4 weeks. |
| AVTX-009 Regimen 2 | DRUG | AVTX-009 will be administered as a subcutaneous injection every 2 weeks. |
| Placebo | DRUG | Matching placebo will be administered as a subcutaneous injection every 2 weeks. |
Inclusion Criteria: 1. Signs and symptoms of hidradenitis suppurativa (HS) for at least 6 months prior to Screening. 2. At least 5 inflammatory lesions in at least 2 distinct anatomical areas, at least 1 of which is Hurley Stage 2 or 3. Exclusion Criteria: 1. Has a draining fistula count of ≥ 20....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |